Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

M5255

Sigma-Aldrich

Mycophenolic acid

from Penicillium brevicompactum, ≥98% (HPLC), powder, IMP dehydrogenase inhibitor

Sinonimo/i:

6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid, 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid, NSC 129185

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C17H20O6
Numero CAS:
24280-93-1
Peso molecolare:
320.34
Beilstein:
1295848
Numero CE:
246-119-3
Numero MDL:
MFCD00036814
Codice UNSPSC:
12352106
ID PubChem:
24896987
NACRES:
NA.77

Nome del prodotto

Mycophenolic acid, ≥98%

Origine biologica

Penicillium brevicompactum

Livello qualitativo

300

Saggio

≥98%

Colore

white to yellow-white

Punto di fusione

<143.0 °C

Solubilità

methanol: 49.00-51.00 mg/mL, clear, colorless to faintly yellow

Modalità d’azione

enzyme | inhibits

Ideatore

Novartis

Temperatura di conservazione

2-8°C

Stringa SMILE

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
HPNSFSBZBAHARI-RUDMXATFSA-N

Informazioni sul gene

human ... IMPDH1(3614) , IMPDH2(3615)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Mycophenolic acid (MPA), produced by Penicillum brevi-compactum, is a selective inhibitor of inosine monphosphate dehydrogenase, thus inhibiting DNA synthesis in T and B lymphocytes. It has also been shown to act as an immunosuppressive agent, and as an inducer of monocyte differentiation and apoptosis in human lymphoid and monocytic cell lines. As a selection agent, MPA is used for transfected animal cells expressing the E. Coli gene for xanthine-guanine phosphoribosyl transferase, and is recommended for use at 25μg/mL.

Azioni biochim/fisiol

Mode of Action: This product acts by suppressing the cytokine-induced nitric oxide production, inhibiting early stage biosynthesis of purine nucleotides and as a specific inhibitor of IMP dehydrogenase.

Caratteristiche e vantaggi

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Avvertenza

As supplied, this product should be stored desiccated at 2-8°C, and is stable for 5 years when stored properly.

Nota sulla preparazione

Mycophenolic acid is soluble in methanol at 50 mg/mL, yielding a colorless to faint yellow solution, as well as chloroform, dichloromethane, ethanol and .1 N NaOH. After reconstitution, the recommendation is to sterilize via filtration thorugh a 0.22 μm pore-size filter, aliquot, and freeze at -20°C.

Avvertenze

Danger

Indicazioni di pericolo

H302,H341,H360D,H372,H410

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Muta. 2 - Repr. 1B - STOT RE 1 Oral

Organi bersaglio

Immune system

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
039M4048V
019M4082V
038M4052V
097M4016V
14161108

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Xanthine sodium salt suitable for cell culture, &#8805;99%

Sigma-Aldrich

X3627

Xanthine sodium salt

Xantina BioUltra, &#8805;99%

Sigma-Aldrich

X4002

Xantina

Mycophenolic acid-d3 solution 1.0&#160;mg/mL in acetonitrile, ampule of 1&#160;mL, certified reference material, Cerilliant&#174;

Supelco

M-180

Mycophenolic acid-d3 solution

6-Azauracil &#8805;98%

Sigma-Aldrich

A1757

6-Azauracil

Mycophenolate mofetil European Pharmacopoeia (EP) Reference Standard

Y0000489

Mycophenolate mofetil

Hypoxanthine powder, BioReagent, suitable for cell culture

Sigma-Aldrich

H9636

Hypoxanthine

Methods for studying activation of matrix metalloproteinases.
V Knäuper et al.
Methods in molecular biology (Clifton, N.J.), 151, 377-387 (2001-02-24)
Burkhard Tönshoff et al.
Transplantation reviews (Orlando, Fla.), 25(2), 78-89 (2011-04-02)
Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppressive therapy in pediatric renal and heart transplant recipients. Children undergo developmental changes (ontogeny) of drug disposition, which may affect drug metabolism of the active compound mycophenolic acid (MPA). Therefore, a detailed
Hylke de Jonge et al.
Therapeutic drug monitoring, 31(4), 416-435 (2009-06-19)
Although therapeutic drug monitoring (TDM) of immunosuppressive drugs has been an integral part of routine clinical practice in solid organ transplantation for many years, ongoing research in the field of immunosuppressive drug metabolism, pharmacokinetics, pharmacogenetics, pharmacodynamics, and clinical TDM keeps
Amy Tarangelo et al.
Life science alliance, 5(4) (2022-01-26)
Nucleotide synthesis is a metabolically demanding process essential for DNA replication and other processes in the cell. Several anticancer drugs that inhibit nucleotide metabolism induce apoptosis. How inhibition of nucleotide metabolism impacts non-apoptotic cell death is less clear. Here, we
Christine E Staatz et al.
Clinical pharmacokinetics, 50(12), 759-772 (2011-11-18)
This review seeks to summarize the available data about Bayesian estimation of area under the plasma concentration-time curve (AUC) and dosage prediction for mycophenolic acid (MPA) and evaluate whether sufficient evidence is available for routine use of Bayesian dosage prediction
Visualizza tutti i documenti correlati

Articoli

Nucleotide Synthesis in Cancer Cells

Neoplastic cells are highly dependent on the de novo synthesis of nucleotides to maintain sufficient pools to support DNA replication and the production of RNA.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.